During the transitional phase of mammographic screening, breast cancer incidence increased. In 1991, breast cancer age-adjusted mortality rates began decreasing and have continued to decrease. In the post-screening phase, stage distribution stabilized, but now with localized and in-situ disease representing the majority of diagnosed cases. The median age at diagnosis has increased to 61 years. and middle income countries (LMICs). Over the past 4 decades, mammographic screening has been one of the most significant changes in breast cancer control strategies in the US and in other high income countries that have similarly seen dropping breast cancer mortality. While much focus has been directed at the mortality impact of mammographic screening, 3 less attention has been paid to how population-based mammographic screening impacts on overall breast cancer demographics, which for countries preparing to implement mammographic screening is important to anticipate. The purpose of this overview is to examine how breast cancer incidence, stage at diagnosis and age at diagnosis changes as mammographic screening is introduced into a previously unscreened population, using historical evidence from SEER in the US as a model. Implications for LMICs where mammographic screening has not been fully implemented will be examined. 
| Breast cancer incidence
Mammographic screening was instituted in the early 1980s as a result of the Health Insurance Plan (HIP) trial in New York. 6 Before 1982 in the prescreening phase, overall breast cancer incidence had been relatively stable, with a similar incidence of both localized (node negative) and regional (node positive) cancers at time of diagnosis, and with in situ disease comprising less than 2% of diagnosed disease. With the introduction of mammographic screening (Fig. 2) , breast cancer incidence rose by about 4% per year between 1982 and 1986, continued to increase through 1991 when breast cancer age-adjusted mortality rates first began to decrease (Fig. 1 ). In the post-screening phase after 1991, breast cancer incidence continued to rise to an age-adjusted rate of 141.4 per 100 000
women by 1999, then declined between 1999 and 2003, and now have stabilized at approx. 127 per 100 000 women since 2003. 7 The mortality and incidence patterns are similar among racial groups in the US, but differences in time course, especially comparing white and black women. While white women have historically had higher incidence rates than black women, the rates converged in 2012. 8 The decrease in breast cancer mortality rates among black women was delayed and did not begin its decrease until after 1995. Unfortunately, the mortality disparity between black and white women nationwide has persisted. In 2012, death rates were still 42% higher among black women than in white women. Whether this difference represents differences in early detection, access to and utilization of treatment or biological differences remains an area of ongoing investigation.
| Stage at diagnosis
The increased breast cancer incidence seen in the US in association with mammographic screening was accompanied by a shift in breast cancer stage distribution toward earlier staged disease. During the transitional phase between the introduction of mammographic screening in 1982 and the subsequent decrease in overall age-adjusted breast cancer mortality in 1991, the rate of localized (node-negative) breast cancers rose from 80 to over 130 cases per 100 000 while DCIS increased from fewer than 5 to more than 30 cases per 100 000. Today in the (Fig. 2) . Today, 20.6% of breast cancer cases diagnosed in the US are in situ disease. when appropriately treated have a more favorable prognosis. 10 
| Age at diagnosis
The increase in breast cancer incidence corresponds to an increase in cancer diagnosis in women aged 50 to 80 years; stratifying incidence rates over time by different age groups demonstrates increasing incidence rates during the transitional phase, but only in women aged 50 years or older and peaking during the 1998-2002 epoch (Fig. 3) . The median age of breast cancer diagnosis has now risen to 61 years in the US. by 1995. 12 Like the US, incidence rates increased, and the majority of breast cancer cases were diagnosed at an earlier stage. 13 Similar patterns in incidence and mortality can be observed in many countries with widespread use of mammography (Fig. 4) ; a review by Anderson et al 14 summarized increases in breast cancer incidence in 18 countries, with accompanying mortality declines in 16. Only two countries had stable mortality rates; both had more a modest increase in incidence over time compared to the other countries.
In a review of 32 countries beginning in 1995, De Santis and colleagues 15 found that mortality declines did not occur in countries without accompanying increases in incidence. Some lower-income countries (eg, Guatemala, Moldova, Philippines, and South Africa)
showed stable or even increasing mortality over time, but incidence trends for these countries were not provided. These findings suggest that early detection efforts, which necessarily increase breast cancer incidence rates but also increase the relative fraction of more favorable biology breast cancers, may be a necessarily prerequisite to improving breast cancer mortality at the population level.
| Early detection programs without mammographic screening
In November 2014, experts from 16 countries met at the International Agency for Research on Cancer (IARC) to assess the cancer-preventive and adverse effects of different methods of breast cancer screening.
This diverse expert group concluded that existing evidence is sufficient to conclude that mammographic screening reduces breast-cancer mortality in women 50-69 years of age. 3 Although mammography screening has contributed to improved breast cancer survival in many countries, such screening programs are often unavailable in LMICs. These countries continue to struggle with | 519 increasing morbidity and mortality from advanced breast cancers, which in many situations comprise the majority of cases diagnosed. It should be noted that, in all these settings, available and improving systemic therapies have also contributed to the mortality declines. In light of the projected increase in breast cancer incidence and mortality in LMICs, exploring alternative methods for achieving down-staging of disease and concomitant reductions in disease via access to appropriate and timely treatment should be a priority.
Therefore, it should be noted that in any setting, breast early detection efforts, regardless of technology or clinical approach used to achieve this outcome, should be offered alongside timely and effective treatment.
In conclusion, population-based mammographic screening promotes well-defined and specific changes in breast cancer demographics. Screening increases breast cancer incidence, particularly of favorable biology, early staged cancers. The median age of diagnosis rises in conjunction with mammographic screening. These features may be necessary for improving breast cancer mortality at the population level, since it has been a near ubiquitous finding among countries where improved mortality has been achieved. It remains unknown if early detection efforts yielding these outcomes can be achieved without mammographic screening using clinical methods based on CBE. Regardless of the early detection method used, cancer detection must be followed by effective and timely cancer treatment if improved mortality rates are to be realized.
